These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1918224)

  • 1. Pharmacokinetics of ceftriaxone.
    Blumer J
    Hosp Pract (Off Ed); 1991 Sep; 26 Suppl 5():7-13; discussion 52-4. PubMed ID: 1918224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of the pharmacokinetics of ceftriaxone in neonates].
    Sunakawa K; Sato Y
    Jpn J Antibiot; 1988 Feb; 41(2):128-32. PubMed ID: 3373735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of ceftriaxone in the first three month of life].
    Rondanelli R; Regazzi MB; Stronati M; Calvi M; Lombardi G; Rondini G
    Pediatr Med Chir; 1992; 14(1):55-9. PubMed ID: 1579518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of ceftriaxone in the neonate.
    Mulhall A; de Louvois J; James J
    Eur J Pediatr; 1985 Nov; 144(4):379-82. PubMed ID: 4076254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients.
    Joynt GM; Lipman J; Gomersall CD; Young RJ; Wong EL; Gin T
    J Antimicrob Chemother; 2001 Apr; 47(4):421-9. PubMed ID: 11266414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics and clinical evaluation of ceftriaxone in neonates].
    Fujii R; Hashira S; Sakata H; Inyaku F; Fujita K; Maruyama S; Yoshioka H; Nakazawa S; Satoh H; Narita A
    Jpn J Antibiot; 1988 Sep; 41(9):1237-50. PubMed ID: 3071615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis.
    Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2016 Dec; 48(6):748-752. PubMed ID: 27838278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Level of evidence for therapeutic drug monitoring of ceftriaxone].
    Dailly E; Verdier MC; Deslandes G; Bouquié R; Tribut O; Bentué-Ferrer D
    Therapie; 2012; 67(2):145-9. PubMed ID: 22850101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of probenecid on the elimination and protein binding of ceftriaxone.
    Stoeckel K; Trueb V; Dubach UC; McNamara PJ
    Eur J Clin Pharmacol; 1988; 34(2):151-6. PubMed ID: 3383987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetic and clinical evaluations on ceftriaxone in neonates and premature infants].
    Shiro H; Kusumoto Y; Satoh Y; Oikawa T; Osano M
    Jpn J Antibiot; 1988 Mar; 41(3):236-43. PubMed ID: 3404644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetic and clinical evaluations on ceftriaxone in neonates].
    Iwai N; Nakamura H; Miyazu M; Katayama M; Taneda Y
    Jpn J Antibiot; 1988 Mar; 41(3):262-75. PubMed ID: 3404646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group a streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling.
    Blumer JL; Reed MD; Kaplan EL; Drusano GL
    Pediatrics; 2005 Oct; 116(4):927-32. PubMed ID: 16199703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.
    Perry TR; Schentag JJ
    Clin Pharmacokinet; 2001; 40(9):685-94. PubMed ID: 11605716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics of ceftriaxone in intensive care].
    Bouget J; Garré M; Reyman JM; Guedes Y; Cartier F
    Pathol Biol (Paris); 1988 Jun; 36(5 Pt 2):706-10. PubMed ID: 3054752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ceftriaxone in liver-transplant recipients.
    Toth A; Abdallah HY; Venkataramanan R; Teperman L; Halsf G; Rabinovitch M; Burckart GJ; Starzl TE
    J Clin Pharmacol; 1991 Aug; 31(8):722-8. PubMed ID: 1880231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics and therapeutic efficacy of ceftriaxone in Chinese adults.
    Zhu Z; Wang AX; Li Y
    Chemotherapy; 1997; 43(3):218-26. PubMed ID: 9142464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of ceftriaxone in plasma and bone of patients undergoing hip or knee surgery.
    Gergs U; Clauss T; Ihlefeld D; Weiss M; Pönicke K; Hofmann GO; Neumann J
    J Pharm Pharmacol; 2014 Nov; 66(11):1552-8. PubMed ID: 24941934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of ceftriaxone.
    Yuk JH; Nightingale CH; Quintiliani R
    Clin Pharmacokinet; 1989 Oct; 17(4):223-35. PubMed ID: 2686882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Free concentration and protein binding of ceftriaxone].
    Saionji K; Miyake N; Miyake K; Igari J; Kobayashi I; Satoh Y
    Jpn J Antibiot; 1992 Feb; 45(2):136-42. PubMed ID: 1613966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections.
    Joos B; Luethy R; Muehlen E; Siegenthaler W
    Am J Med; 1984 Oct; 77(4C):59-62. PubMed ID: 6093521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.